|
1
|
Reduced Paneth cell alpha-defensins in ileal Crohn's disease.
|
Proc Natl Acad Sci U S A
|
2005
|
5.05
|
|
2
|
NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium.
|
Infect Immun
|
2004
|
2.47
|
|
3
|
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study.
|
BMJ
|
2012
|
2.32
|
|
4
|
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis.
|
Inflamm Bowel Dis
|
2003
|
2.06
|
|
5
|
The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4.
|
J Immunol
|
2007
|
1.73
|
|
6
|
Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease.
|
Eur J Gastroenterol Hepatol
|
2002
|
1.59
|
|
7
|
Mitochondrial gene polymorphisms that protect mice from colitis.
|
Gastroenterology
|
2013
|
1.53
|
|
8
|
Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin.
|
Infect Immun
|
2007
|
1.48
|
|
9
|
Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4.
|
JAMA
|
2012
|
1.47
|
|
10
|
The expression patterns of peritoneal defensins.
|
Perit Dial Int
|
2007
|
1.39
|
|
11
|
Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis.
|
Differentiation
|
2008
|
1.30
|
|
12
|
Mechanisms of disease: defensins in gastrointestinal diseases.
|
Nat Clin Pract Gastroenterol Hepatol
|
2005
|
1.27
|
|
13
|
Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease.
|
J Leukoc Biol
|
2004
|
1.26
|
|
14
|
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease.
|
PLoS One
|
2009
|
1.24
|
|
15
|
Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases.
|
Eur J Gastroenterol Hepatol
|
2006
|
1.21
|
|
16
|
Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease.
|
J Leukoc Biol
|
2007
|
1.14
|
|
17
|
Reduced mucosal antimicrobial activity in Crohn's disease of the colon.
|
Gut
|
2007
|
1.11
|
|
18
|
A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts.
|
J Microbiol Methods
|
2005
|
1.05
|
|
19
|
Antibacterial activity of human defensins on anaerobic intestinal bacterial species: a major role of HBD-3.
|
Microbes Infect
|
2009
|
1.03
|
|
20
|
Crohn's disease--defect in innate defence.
|
World J Gastroenterol
|
2008
|
0.97
|
|
21
|
The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease.
|
Am J Pathol
|
2010
|
0.96
|
|
22
|
Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2.
|
J Crohns Colitis
|
2012
|
0.90
|
|
23
|
Thiopurines in inflammatory bowel disease revisited.
|
World J Gastroenterol
|
2013
|
0.88
|
|
24
|
A novel multiplex-protein array for serum diagnostics of colon cancer: a case-control study.
|
BMC Cancer
|
2012
|
0.87
|
|
25
|
Human defensins in Crohn's disease.
|
Chem Immunol Allergy
|
2005
|
0.86
|
|
26
|
Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis.
|
Inflamm Bowel Dis
|
2004
|
0.85
|
|
27
|
Fatal staphylococcal sepsis in Crohn's disease after infliximab.
|
Inflamm Bowel Dis
|
2004
|
0.85
|
|
28
|
Herpes simplex virus colitis complicating ulcerative colitis: A case report and brief review on superinfections.
|
J Crohns Colitis
|
2007
|
0.83
|
|
29
|
Crohn's targeted therapy: myth or real goal?
|
Curr Drug Discov Technol
|
2009
|
0.82
|
|
30
|
Mesenteric pulsatility index analysis predicts response to azathioprine in patients with Crohn's disease.
|
Inflamm Bowel Dis
|
2005
|
0.80
|
|
31
|
Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein.
|
Inflamm Bowel Dis
|
2004
|
0.78
|
|
32
|
Antimicrobial peptides in the skin.
|
N Engl J Med
|
2003
|
0.78
|
|
33
|
Does etiology of acute pancreatitis matter? A review of 391 consecutive episodes.
|
JOP
|
2015
|
0.77
|
|
34
|
Colorectal neoplasia in IBD--a single-center analysis of patients undergoing proctocolectomy.
|
Int J Colorectal Dis
|
2015
|
0.76
|
|
35
|
Risk factors for development of hemolytic uremic syndrome in a cohort of adult patients with STEC 0104:H4 infection.
|
PLoS One
|
2013
|
0.76
|
|
36
|
Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment.
|
Eur J Gastroenterol Hepatol
|
2015
|
0.75
|
|
37
|
[Not Available].
|
Med Klin (Munich)
|
2010
|
0.75
|
|
38
|
[Not Available].
|
Med Klin (Munich)
|
2010
|
0.75
|
|
39
|
6-thioguanine-buried alive?
|
Gastroenterology
|
2004
|
0.75
|
|
40
|
[Not Available].
|
Med Klin (Munich)
|
2010
|
0.75
|
|
41
|
Therapeutic peptides in inflammatory bowel disease.
|
Expert Opin Biol Ther
|
2014
|
0.75
|
|
42
|
Cyclophosphamide therapy in Sweet's syndrome complicating refractory Crohn's disease − Efficacy and mechanism of action.
|
J Crohns Colitis
|
2011
|
0.75
|